Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far
beyond their remarkable clinical efficacy in some patients. It creates radical changes in the …

Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

Novel patterns of response and progression to immunotherapy have been reported that are
not observed with conventional cytotoxic or targeted anticancer treatments. A major …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe,
Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized …

Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …

PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …